Benlysta® (belimumab – GSK) has received an expanded indication to treat active lupus nephritis in patients who are at least five years old and receiving standard therapy.

• In 2011 Benlysta was given FDA approval for treatment of systemic lupus erythematosus and lupus nephritis treatment in It has now been indicated to treat both active systemic lupus erythematosus and lupus nephritis in patients who are at least five years old and receiving standard therapy.
• Recommended dosing is based on the patient’s age, diagnosis, and weight.